Current Report Filing (8-k)
February 10 2017 - 6:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
February 10, 2017
Date of report (Date of earliest event reported)
Nexvet
Biopharma
public limited company
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
Ireland
|
|
001-36828
|
|
98-1205017
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98, Ireland
(Address of principal executive offices, including zip code)
+353 5793 24522
(Registrants telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On February 10, 2017, Nexvet Biopharma public
limited company (the Company) reported its financial results for the second quarter of fiscal year 2017 (the quarterly period ended December 31, 2016). The Companys earnings release for this period is furnished herewith as
Exhibit 99.1.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Earnings release dated February 10, 2017 announcing the Companys financial results for the second quarter of fiscal year 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
Nexvet Biopharma public limited company
|
|
|
By:
|
|
/s/ Mark Heffernan, Ph.D.
|
Name:
|
|
Mark Heffernan
|
Its:
|
|
Chief Executive Officer
|
Date: February 10, 2017
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Mar 2024 to Apr 2024
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Apr 2023 to Apr 2024